.Pharmacolibrary.Drugs.C_CardiovascularSystem.C01D_VasodilatorsUsedInCardiacDiseases.C01DX21_Serelaxin.Serelaxin .Pharmacolibrary.Drugs.C_CardiovascularSystem.C01D_VasodilatorsUsedInCardiacDiseases.C01DX21_Serelaxin.Serelaxin| name: | Serelaxin |
| ATC code: | C01DX21 | route: | intravenous |
| n-compartments | 2 |
Serelaxin is a recombinant form of human relaxin-2, a hormone involved in the cardiovascular and renal adaptive changes during pregnancy. It has been developed as a treatment for acute heart failure but is not approved for use by regulatory agencies as of 2024.
PK parameters reported in patients with acute heart failure following 48-hour intravenous infusion.
Soubret, A, et al., & Dahlke, M (2018). Population pharmacokinetics of serelaxin in patients with acute or chronic heart failure, hepatic or renal impairment, or portal hypertension and in healthy subjects. British journal of clinical pharmacology 84(11) 2572–2585. DOI:10.1111/bcp.13714 PUBMED:https://pubmed.ncbi.nlm.nih.gov/30014598
Dahlke, M, et al., & Pang, Y (2015). Safety and tolerability of serelaxin, a recombinant human relaxin-2 in development for the treatment of acute heart failure, in healthy Japanese volunteers and a comparison of pharmacokinetics and pharmacodynamics in healthy Japanese and Caucasian populations. Journal of clinical pharmacology 55(4) 415–422. DOI:10.1002/jcph.433 PUBMED:https://pubmed.ncbi.nlm.nih.gov/25408331
Sato, N, et al., & Kawana, M (2015). Multicenter, Randomized, Double-Blinded, Placebo-Controlled Phase II Study of Serelaxin in Japanese Patients With Acute Heart Failure. Circulation journal : official journal of the Japanese Circulation Society 79(6) 1237–1247. DOI:10.1253/circj.CJ-15-0227 PUBMED:https://pubmed.ncbi.nlm.nih.gov/25912697